Strategic Dives

9:00 am

Discovery

A

Armoured CAR & TCR Constructs to Create Better Killers

• Explore novel gene engineered CAR-T and TCR constructs which enhance potency and overcome the suppressive nature of the tumor microenvironment
• Review the effect of stripping inhibitory receptors to create anti-T-cell CAR-T
• Identify accessory proteins which help enhance efficacy

Thomas Andresen, Chief Scientific Officer, Torque Therapeutics

Translation
Manufacturing
Logistics
Commercialization

11:00 am Morning Refreshments & Debrief

12:00 pm

Discovery

F

Antigen Identification for Clean Targets

• Review potential approaches to minimize off-target toxicity by identifying tumor-specific antigens at which to target CAR T cells
• Discuss strategies to identify antigens found primarily or exclusively on tumor cells that could be targets for CART
therapy

Blake Aftab, Vice President of Translational Science, Atara Biotherapeutics

Translation
Manufacturing
Logistics
Commercialization

2:00 pm Afternoon Refreshments & Debrief

3:00 pm

Discovery

K

Density Selective Target Binding to Improve Specificity & CAR T Cell Function

• Detail how increased selectivity by affinity tuning the targeting moiety can result in desired CAR T cell function
• Review partial CAR T cell signalling to amplify natural T cell activity
• Discuss how affinity and signalling selection can enhance solid tumor activity

Eric von Hofe, President, AffyImmune Therapeutics

Translation
Manufacturing
Logistics
Commercialization

5:00 pm Evening Refreshments & Debrief

6:00 pm Ambassador Reception, Hosted by Bio-Rad

6:30 pm Women of CAR-TCR Round Table Discussion